Image

Middle East and Africa Age-Related Macular Degeneration (AMD) Disease Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Published Report
  • Jun 2022
  • MEA
  • 350 Pages
  • No of Tables: 60
  • No of Figures: 33

Middle East and Africa Age-Related Macular Degeneration (AMD) Disease Market, By Type (Dry AMD and Wet AMD), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare and Others), Distribution Channel (Direct Tender and Retail Sales) Industry Trends and Forecast to 2029

Middle East and Africa Age-Related Macular Degeneration (AMD) Disease Market

Market Analysis and Insights

Middle East and Africa age-related macular degeneration (AMD) disease market is driven by the factors such as, rising geriatric population, increase in the prevalence of age-related macular degeneration (AMD) disease and pipeline products enhance its demand as well as rising investment in research and development leads to the market growth. Currently, healthcare expenditure has increased across developed and emerging countries that is expected to create a competitive advantage for manufacturers to develop new and innovative products.

Middle East and Africa Age-Related Macular Degeneration (AMD) Disease Market

 

Middle East and Africa Age-Related Macular Degeneration (AMD) Disease Market

The prevalence of age-related macular degeneration, is expected to increase in developed countries due to the aging population and rising life expectancy. It is estimated that nearly 60% of patients have severe visual impairment occurring disease shortly after birth. This disease leads to blurring central vision in the patient’s eye. The demand for age-related macular degeneration (AMD) disease treatment and diagnostic has been increased more in the developed countries. However, the high cost associated with the treatment and procedure as well as stringent government regulations for product approval are expected to hamper the growth for age-related macular degeneration (AMD) disease market.

Middle East and Africa age-related macular degeneration (AMD) disease market is supportive and aims to reduce the progression of the disease. Data Bridge Market Research analyses that Middle East and Africa age-related macular degeneration (AMD) disease market will grow at a CAGR of 6.0% during the forecast period of 2022 to 2029.

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Year

2020 (Customizable to 2019 - 2014)

Quantitative Units

Revenue in USD Million

Segments Covered

By Type (Dry AMD and Wet AMD), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare and Others), Distribution Channel (Direct Tender and Retail Sales) Industry Trends and Forecast to 2029

Countries Covered

By Country (Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2029

Market Players Covered

Novartis AG, Bayer AG, Johnson & Johnson Services, Inc, Adverum Biotechnologies, Inc. among others

Market Definition

Age-related macular degeneration (AMD) is an eye disease that can cause damage to the macula part of the eye that controls sharp and straight-ahead vision. This leads to blurring central vision. Vision loss can be caused by abnormal blood vessel growth. Sometimes abnormal new blood vessels grow from the choroid under and into the macula. The choroid is the layer of blood vessels between the retina and the outer, firm coat of the eye (sclera). These abnormal blood vessels may leak fluid or blood, interfering with the retina's function. Macular degeneration is common in aging people. Other reasons for the rising of procedures can be defined by the increasing aging people causes and the requirement for healthcare facilities, including treatment for patient-friendly techniques for diagnosis where the medical requirements are maximum, which can further decrease the burden on healthcare facilities.

The diagnosis and treatment of age-related macular degeneration (AMD) disease consist of various techniques that allow diagnosis of the disease after the approval of the product. The treatment for the disease is recently approved, which supports the market growth. However, these treatments are expensive and not available to all patients.

Middle East and Africa Age-Related Macular Degeneration (AMD) Disease Market Dynamics

Drivers

  • Rising geriatric population

The world’s geriatric population is increasing at a rapid rate. With the increasing age comes a reciprocal increase in the number of elderly patients due to the rising prevalence of chronic disease. Age is a severe risk factor for any disease progression as age is an essential parameter that affects fundamental biological mechanisms. Therefore, aging is one of the risk factors for the Middle East and Africa incidence of early AMD. Age-related macular degeneration (AMD) can cause damage to the macula part of the eye. This leads to blur central vision. It can cause irreversible blindness and is the leading cause of visual impairment in the elderly people.

Macular degeneration is more common in aging people. The diagnosis of disease is possible at various stages and number of genetic testing and retinal imaging are some of the techniques for the detection of disease. The diagnosis of the disease is conducted mainly by optical imaging techniques and other standard process. Thus, the increasing rate of the geriatric population is expected to drive the growth of the Middle East and Africa age-related macular degeneration (AMD) disease market growth.

  • Increasing Prevalence of Age-Related Macular Degeneration (AMD) Disease

The demand for age-related macular degeneration (AMD) disease treatment and diagnostic has been increased more in the developed countries. These countries had reimbursement policies for age-related macular degeneration (AMD) disease market along with that increasing prevalence of genetic diseases.

Thus, it signifies that increasing prevalence of age-related macular degeneration (AMD) disease is expected to drive the Middle East and Africa age-related macular degeneration (AMD) disease market growth.

Opportunity

  •  Rising Research and Development 

Research and development is a prerequisite to modifying the treatment intended to treat different kinds of patients. The demand for age-related macular degeneration (AMD) treatment and procedures increasing worldwide involving every country Middle East and Africa. This is why the companies are continuously focusing on research and development in order to achieve success in providing effective treatment to patients and healthcare workers.

The effects can be seen only for individuals in certain ways that include effective potentiating factors such as the disease evolves, vision becomes progressively more compromised, the retinal tissue degenerates, and suffering permanent damage.

As the companies are constantly engaged in developmental activities more innovative products are launched in the market. This thus signifies that increasing research and development is expected as an opportunity for the Middle East and Africa age-related macular degeneration (AMD) disease growth. The various programs and decisions taken by the government around the world for giving the best treatment to their population is the major factor that is expected to increase the demand and will act as an opportunity for the Middle East and Africa age-related macular degeneration (AMD) disease market.

Restraint/Challenge

  • High Cost Of Aesthetic Surgical Procedures

The cost of the product plays a major factor in the market. In the age-related macular degeneration (AMD) disease, it is generally observed that they are highly sophisticated, need to be precise, and other specifications increase the product's cost. Moreover, the cost associated with treatment for a longer duration is quite difficult for an average-income person to afford. Utilizations of critical care and intensive care unit services are increasing worldwide, along with their expensive cost is a major concern in the current healthcare system.

Patients with degeneration disorder are commonly required to have long treatment with frequent monetarization and other usage leading to consuming a significant amount of healthcare resources. Due to this, most patients who cannot afford long-term economic costs get discharged in the initial stages of treatment.  But this increases the possibilities and susceptibilities for new complications in the diagnosis which demands additional healthcare resources and treatment. As the cost of innovative and advanced products is high, the cost of the treatment proportionally gets escalated, due to which high cost associated with age-related macular degeneration (AMD) disease treatment and diagnosis is expected to restrain the Middle East and Africa age-related macular degeneration (AMD) disease market growth.

Recent Developments

  • In January 2022, Genentech, Inc announced that the U.S. Food and Drug Administration (FDA) has approved Vabysmo (faricimab-svoa) for the treatment of wet AMD and DME. This will help the company to commercialize the product in the market in the forecast period.
  • In April 2022, Graybug Vision Inc. announced that the company has presented a poster presentation preclinical data at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting for GB-401 in primary open-angle glaucoma (POAG). This will increase the chances for safety and evaluation of drug in the market.

Middle East and Africa Age-Related Macular Degeneration (AMD) Disease Market Segmentation

Middle East and Africa age-related macular degeneration (AMD) disease market is categorized into is categorized into three notable segments which are based on type, end user and distribution channel. The growth among segments helps you analyses niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Type

  • Dry AMD
  • Wet AMD

On the basis of type, the Middle East and Africa age-related macular degeneration (AMD) disease market is segmented into dry AMD and wet AMD.

End User

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Home Healthcare
  • Others

On the basis of end user, the Middle East and Africa age-related macular degeneration (AMD) disease market is segmented into hospitals, specialty clinics, ambulatory surgical centers, home healthcare and others.

Distribution Channel

  • Retail Sales
  • Direct Tender

Age-Related Macular Degeneration (AMD) Disease Market

On the basis of distribution channel, the Middle East and Africa age-related macular degeneration (AMD) disease market is segmented into retail sales and direct tender.

Age-Related Macular Degeneration (AMD) Disease Market Regional Analysis/Insights

The age-related macular degeneration (AMD) disease market is analysed and market size insights and trends are provided by type, end user and distribution channel as referenced above.

The countries covered in the age-related macular degeneration (AMD) disease report are Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt and Rest of Middle East and Africa.

South Africa is expected to dominate due to increasing technological advancement in the developing areas.

The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Middle East and Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Age-Related Macular Degeneration (AMD) Disease Market Share Analysis

Middle East and Africa age-related macular degeneration (AMD) disease market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Middle East and Africa presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on age-related macular degeneration (AMD) disease market.

Some of the players in the market are Novartis AG, Bayer AG, Johnson & Johnson Services, Inc, Adverum Biotechnologies, Inc. among others.

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analysed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Middle East and Africa vs Regional and Vendor Share Analysis. Please request analyst call in case of further inquiry.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

TABLE 1 VARIOUS EXAMPLES OF OPHTHALMIC DEVICES ARE SUMMARIZED IN THE BELOW-GIVEN TABLE ACCORDING TO THEIR CLASSIFICATION

TABLE 2 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 3 MIDDLE EAST & AFRICA DRY AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 4 MIDDLE EAST & AFRICA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 5 MIDDLE EAST & AFRICA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 6 MIDDLE EAST & AFRICA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 7 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 8 MIDDLE EAST & AFRICA HOSPITALS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 9 MIDDLE EAST & AFRICA SPECIALTY CLINICS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 10 MIDDLE EAST & AFRICA AMBULATORY SURGICAL CENTERS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 11 MIDDLE EAST & AFRICA HOME HEALTHCARE IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 12 MIDDLE EAST & AFRICA OTHERS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 13 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL , 2020-2029 (USD MILLION)

TABLE 14 MIDDLE EAST & AFRICA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 15 MIDDLE EAST & AFRICA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 16 MIDDLE EAST & AFRICA DIRECT TENDER IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 17 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 18 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 19 MIDDLE EAST & AFRICA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 20 MIDDLE EAST & AFRICA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 21 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 22 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 23 MIDDLE EAST & AFRICA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 24 SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 25 SOUTH AFRICA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 26 SOUTH AFRICA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 27 SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 28 SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 29 SOUTH AFRICA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 30 SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 31 SAUDI ARABIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 32 SAUDI ARABIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 33 SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 34 SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 35 SAUDI ARABIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 36 UAE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 37 UAE WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 38 UAE MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 39 UAE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 40 UAE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 41 UAE RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 42 ISRAEL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 43 ISRAEL WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 44 ISRAEL MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 45 ISRAEL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 46 ISRAEL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 47 ISRAEL RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 48 EGYPT AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 49 EGYPT WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 50 EGYPT MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 51 EGYPT AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 52 EGYPT AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 53 EGYPT RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 54 KUWAIT AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 55 KUWAIT WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 56 KUWAIT MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 57 KUWAIT AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 58 KUWAIT AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 59 KUWAIT RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 60 REST OF MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions



Frequently Asked Questions